Apellis Pharmaceuticals, Inc. (APLS) Misses Q2 EPS by 5c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q2 EPS of ($1.46), $0.05 worse than the analyst estimate of ($1.41). Revenue for the quarter came in at $16.3 million versus the consensus estimate of $16.95 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Morgan Stanley upgrades CDW on stronger AI-driven server demand